AcelRx Pharmaceuticals Inc. (ACRX)

2.90
NASDAQ : Health Technology
Prev Close 2.79
Day Low/High 2.75 / 2.93
52 Wk Low/High 1.99 / 5.05
Avg Volume 2.39M
Exchange NASDAQ
Shares Outstanding 78.91M
Market Cap 220.17M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Stocks Under $10 Weekly Summary

We took some nice profits trimming a position, exited a name and added to another holding during a challenging week for stocks.

AcelRx Pharmaceuticals Reports First Quarter 2019 Financial Results

AcelRx Pharmaceuticals Reports First Quarter 2019 Financial Results

REDWOOD CITY, Calif., May 8, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

Stocks Under $10 Weekly Summary

We added to three positions and pulled the plug on another during a solid week for small-cap stocks.

Stocks Under $10 Weekly Summary

We ditched one position and added to another last week as small-cap stocks trended higher.

First Week Of December 20th Options Trading For AcelRx Pharmaceuticals (ACRX)

First Week Of December 20th Options Trading For AcelRx Pharmaceuticals (ACRX)

Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

AcelRx To Announce First Quarter 2019 Results And Provide An Update On The Company's Business On Wednesday, May 8th, 2019

AcelRx To Announce First Quarter 2019 Results And Provide An Update On The Company's Business On Wednesday, May 8th, 2019

REDWOOD CITY, Calif., April 25, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

Stocks Under $10 Weekly Summary

During the week, we took a starter position in Encana Corp. and boosted our cash position by trimming iShares Russell 2000 ETF.

Stocks Under $10 Weekly Summary

We made several trades last week as the overall market grinded modestly higher.

Stocks Under $10 Weekly Summary

The portfolio had a strong start to the June quarter, due in part to the small cap-heavy Russell 2000 leading the market higher.

Stocks Under $10 Weekly Summary

Last week was a very strong one for many of our positions as the domestic market ended the first quarter on a high note.

Stocks Under $10 Weekly Summary

During the week we brought Fitbit back into the portfolio and added Digital Turbine to the Bullpen.

Stocks Under $10 Weekly Summary

Last week was a very good one for the portfolio as nine of our 13 holdings outperformed our benchmark, the Russell 2000.

Stocks Under $10 Weekly Summary

We initiated one position and exited another during a tough week for small-cap stocks.

AcelRx Pharmaceuticals To Present At Oppenheimer & Co. Inc. 29th Annual Healthcare Conference

AcelRx Pharmaceuticals To Present At Oppenheimer & Co. Inc. 29th Annual Healthcare Conference

REDWOOD CITY, Calif., March 11, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

Two of Our Portfolio Holdings Go to the Tape

Is action required for AcelRx Pharmaceuticals and Energy Recovery?

AcelRx Pharmaceuticals Announces Commercial Launch Of DSUVIA And Reports Fourth Quarter And Full Year 2018 Financial Results

AcelRx Pharmaceuticals Announces Commercial Launch Of DSUVIA And Reports Fourth Quarter And Full Year 2018 Financial Results

- DSUVIA now available for use in certified medically supervised healthcare settings, with initial shipments to wholesalers completed in the second half of February 2019

Stocks Under $10 Weekly Summary

We rang the register on part of a high-flying position and added to another on weakness.

Stocks Under $10 Weekly Summary

With the small-cap heavy Russell 2000 leading the major market index pack last week, we saw a number of pronounced moves higher in the portfolio.

Stocks Under $10 Weekly Summary

Another melt-up for the stock market, together with a late-Friday surge was a positive for several portfolio holdings.

Stocks Under $10 Weekly Summary

We closed our position in Fitbit for a healthy profit and added twice to USA Technologies last week.

Stocks Under $10 Weekly Summary

We booked hefty wins last week exiting Blue Apron and GE and trimming our position in Fitbit.

Stocks Under $10 Weekly Summary

While the overall stock market finished last week essentially unchanged, the portfolio had several outperformers.

First Week Of September 20th Options Trading For AcelRx Pharmaceuticals (ACRX)

First Week Of September 20th Options Trading For AcelRx Pharmaceuticals (ACRX)

Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the September 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Stocks Under $10 Weekly Summary

We added one new position and doubled down on another during a very good week for the portfolio.

Stocks Under $10 Weekly Summary

We exited two positions last week as the portfolio and the market started off the year in the green.

AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Data On Sufentanil Sublingual Tablets For Short-term Treatment Of Moderate-to-severe Acute Pain

AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Data On Sufentanil Sublingual Tablets For Short-term Treatment Of Moderate-to-severe Acute Pain

- Over 800 patients from AcelRx studies supporting DSUVIA™ approval were included in the pooled safety analysis

Interesting ACRX Put Options For February 15th

Interesting ACRX Put Options For February 15th

Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACRX options chain for the new February 15th contracts and identified the following put contract of particular interest.

TheStreet Quant Rating: D- (Sell)